On Air Now

Listen

Listen Live Now » 101.1 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
62° Feels Like: 62°
Wind: WSW 0 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Clear 57°

Tomorrow

Scattered Thunderstorms 79°

Sat Night

Thunderstorms Early 57°

Alerts

New British biotech firm to tap gene therapy for blindness

LONDON (Reuters) - Oxford scientists have set up a biotechnology company to develop the use of gene therapy in treating blindness, and the Wellcome Trust medical charity has invested 12 million pounds ($20 million) in the start-up.

NightstaRx plans to develop and sell therapies for retinal dystrophies - degenerative conditions affecting vision - by building on work carried out at the University of Oxford's Nuffield Laboratory of Ophthalmology, it said on Thursday.

Oxford-based researchers reported two weeks ago that an early-stage clinical trial using gene therapy had shown promise in a handful of patients with a progressive form of blindness called choroideremia.

The company has an exclusive license to the intellectual property underpinning the Oxford gene therapy programme.

Choroideremia is caused by a mutation in a gene that makes a protein called REP1. It affects an estimated one in 50,000 people and causes sufferers, who are mainly men, to lose their sight gradually as the cells in the retina degenerate.

($1 = 0.6041 British pounds)

(Reporting by Ben Hirschler; Editing by Louise Ireland)

Comments